After the Diagnosis of Dementia: Considerations in Disease Management
Author:
Hoover Steven,Sano Mary
Publisher
Springer New York
Reference70 articles.
1. Burgener SC, Berger B. Measuring perceived stigma in persons with progressive neurological disease: Alzheimer’s dementia and Parkinson’s disease. Dementia. 2008;7:31–53.
2. Kraemer HC, Tinklenberg J, Yesavage JA. ‘How far’ vs ‘how fast’ in Alzheimer disease: the question revisited. Arch Neurol. 1994;51:275–9.
3. Behuniak SM. The living dead? The construction of people with Alzheimer’s disease as zombies. Ageing Soc. 2011;31:70–92.
4. Kaye ED, Petrovic-Poljak A, Verhoeff NPLG, Freedman M. Frontotemporal dementia and pharmacologic interventions. J Neuropsychiatry Clin Neurosci. 2010;22:19–29.
5. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.